Identification of novel inhibitors targeting entry of human cytomegalovirus

针对人类巨细胞病毒进入的新型抑制剂的鉴定

• 批准号: 8403863
• 负责人: Domenico Tortorella
• 金额: $ 4.24万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-15 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8403863
• 关键词: Acquired Immunodeficiency Syndrome; Adverse effects; Affect; Anemia; Attenuated; Autoimmune Diseases; Autoimmune Process; Biological Assay; Cancer Patient; Cardiovascular Diseases; Chemicals; Clinical; Congenital Abnormality; Cytomegalovirus; Cytomegalovirus Infections; DNA biosynthesis; DNA-Directed DNA Polymerase; Developed Countries; Disease; Drug resistance; Elderly; Failure; Fibroblasts; Functional disorder; Ganciclovir; Gene Expression; Generations; Genomics; Goals; Grant; HIV; Hour; Human; Immediate-Early Genes; Immediate-Early Proteins; Immunocompromised Host; Immunosuppressive Agents; Individual; Infant; Infection; Lead; Life Cycle Stages; Malignant Neoplasms; Molecular; Molecular Profiling; Morbidity - disease rate; Neutropenia; Newborn Infant; Nuclear; One-Step dentin bonding system; Organ; Organ Transplantation; Patients; Pharmaceutical Preparations; Phase; Population; Process; Proteins; Reagent; Regimen; Replication Licensing; Reporting; Retinitis; Risk; Severities; Signal Transduction; Signaling Protein; Therapeutic; Thrombocytopenia; Toxic effect; Transplant Recipients; Transplantation; United States; United States National Institutes of Health; Valganciclovir; Validation; Variant; Viral; Viral Genes; Viral Genome; Viral Load result; Viral Proteins; Virion; Virus; Virus Diseases; Virus Replication; alternative treatment; drug resistant virus; high risk; high throughput screening; immune function; inhibitor/antagonist; latent persistent infection; mortality; neonate; novel; novel therapeutics; older patient; pathogen; patient population; prevent; small molecule; standard of care; viral DNA

DESCRIPTION (provided by applicant): Human cytomegalovirus (HCMV) is an opportunistic pathogen with the ability to establish and maintain a lifelong relationship with its host, a persistent state termed latency. Primary infections and reactivation of latent HCMV results in a high viral load in patients with inadequate immune function commonly results in uncontrolled virus replication, and multi-organ disease and dysfunction. In fact, HCMV significantly contributes to morbidity and mortality in immunocompromised individuals such as newborns, organ transplant recipients, AIDS patients, cancer patients, patients with cardiovascular diseases, autoimmune disease patients, as well as the elderly. HCMV is the leading cause of birth defects affecting 1-4% of newborns in developed countries and significantly contributes to transplant failure. HCMV also increases the severity of cardiovascular diseases, autoimmune diseases, and various cancers. Current therapy against HCMV targets the viral DNA polymerase, but induces severe side effects (e.g. thrombocytopenia) and drug-resistant viral strains upon prolonged treatment. Our central hypothesis is that inhibiting HCMV proliferation by targeting diverse steps of the HCMV life cycle would effectively limit HCMV-associated diseases. Thus, we propose to identify novel therapeutics that inhibit the early steps of HCMV infection utilizing a HCMV variant that expresses a viral protein (immediate-early protein 2) fused to yellow fluorescent protein. A high-content screen will be performed at the NIH Chemical Genomics Core to identify compounds that block the early steps of virus infection. High- throughput secondary assays will be performed to identify lead compounds through their validation in a diverse high-content screen, an effective concentration in the nanomolar range and low toxicity. Also, tertiary assays will define the mode of action of the lead compounds. The discovery of anti-HCMV reagents against the early phase of infection represents a novel class of compounds that will target different proteins than the current therapeutics with the objective o attenuating HCMV proliferation and HCMV-associated diseases in immunocompromised individuals.

描述（由申请人提供）：人类巨细胞病毒（HCMV）是一种机会性病原体，具有与宿主建立并维持终身关系的能力，这种持续状态称为潜伏期。在免疫功能不足的患者中，原发性感染和潜伏HCMV的再激活导致高病毒载量，通常导致病毒复制不受控制，以及多器官疾病和功能障碍。事实上，HCMV对免疫功能低下个体（如新生儿、器官移植受者、艾滋病患者、癌症患者、心血管疾病患者、自身免疫性疾病患者以及老年人）的发病率和死亡率有显著影响。HCMV是导致出生缺陷的主要原因，影响发达国家1-4%的新生儿，并严重导致移植失败。HCMV还会增加心血管疾病、自身免疫性疾病和各种癌症的严重程度。目前针对HCMV的治疗以病毒DNA聚合酶为靶点，但在长期治疗后会引起严重的副作用（如血小板减少症）和耐药病毒株。我们的中心假设是，通过靶向HCMV生命周期的不同步骤来抑制HCMV增殖将有效地限制HCMV相关疾病。因此，我们建议利用一种表达病毒蛋白（即早期蛋白2）与黄色荧光蛋白融合的HCMV变体来识别抑制HCMV感染早期阶段的新疗法。高含量筛选将在美国国立卫生研究院化学基因组学中心进行，以确定阻断病毒感染早期步骤的化合物。高通量二级分析将通过在不同的高含量筛选、纳摩尔范围内的有效浓度和低毒性中进行验证来鉴定先导化合物。此外，三级分析将确定先导化合物的作用方式。针对感染早期阶段的抗HCMV试剂的发现代表了一类新的化合物，它将针对不同的蛋白质，而不是目前的治疗方法，目的是减轻免疫功能低下个体的HCMV增殖和HCMV相关疾病。